Everest Medicines Ltd
HKEX:1952
If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
14.54
39.5
|
| Price Target |
|
We'll email you a reminder when the closing price reaches HKD.
Choose the stock you wish to monitor with a price alert.
This alert will be permanently deleted.
Everest Medicines Ltd
Revenue
Everest Medicines Ltd
Revenue Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Revenue | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
E
|
Everest Medicines Ltd
HKEX:1952
|
Revenue
¥125.9m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Beigene Ltd
HKEX:6160
|
Revenue
¥17.4B
|
CAGR 3-Years
102%
|
CAGR 5-Years
68%
|
CAGR 10-Years
N/A
|
|
|
Akeso Inc
HKEX:9926
|
Revenue
¥4.5B
|
CAGR 3-Years
N/A
|
CAGR 5-Years
337%
|
CAGR 10-Years
N/A
|
|
|
Beijing Wantai Biological Pharmacy Enterprise Co Ltd
SSE:603392
|
Revenue
¥5.5B
|
CAGR 3-Years
33%
|
CAGR 5-Years
41%
|
CAGR 10-Years
N/A
|
|
|
Shanghai RAAS Blood Products Co Ltd
SZSE:002252
|
Revenue
¥8.3B
|
CAGR 3-Years
37%
|
CAGR 5-Years
31%
|
CAGR 10-Years
27%
|
|
|
Chongqing Zhifei Biological Products Co Ltd
SZSE:300122
|
Revenue
¥36.4B
|
CAGR 3-Years
12%
|
CAGR 5-Years
31%
|
CAGR 10-Years
47%
|
|
Everest Medicines Ltd
Glance View
Everest Medicines Ltd. operates as a biopharmaceutical company which focuses on licensing, clinical development and commercialization of globally therapies to address critical unmet medical needs in Greater China and other emerging Asia Pacific markets. The company is headquartered in Shanghai, Shanghai and currently employs 405 full-time employees. The company went IPO on 2020-10-09. The firm is focusing on the research and development of innovative drug candidate. The firm built a portfolio of promising clinical-stage drug candidates across oncology, immunology, cardio-renal disease and infectious disease. The firm mainly provides its products and services in Greater China and other emerging Asia Pacific markets.
See Also
What is Everest Medicines Ltd's Revenue?
Revenue
125.9m
CNY
Based on the financial report for Dec 31, 2023, Everest Medicines Ltd's Revenue amounts to 125.9m CNY.
What is Everest Medicines Ltd's Revenue growth rate?
Revenue CAGR 1Y
884%
Over the last year, the Revenue growth was 884%.
You don't have any saved screeners yet
